Clinical Trial

A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma

Name: A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07726160)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: KIV-318

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A single-arm, open-label, multicenter, dose-escalation clinical trial to evaluate the safety, tolerability, and preliminary efficacy of KIV-318 Injection in patients with relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07726160
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Shenzhen Pregene Biopharma Co., Ltd.
Conditions	Relapse and/or Refractory Multiple Myeloma
Enrollment	30 participants
Start Date	2026-07-20
Primary Completion	2029-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-24